Market Currents
Mylan (MYL +0.9%) gets a boost today from an upgrade to Outperform at Leerink Swann, citing a...
-
Friday, November 16, 2012, 1:02 PM ETMylan (MYL +0.9%) gets a boost today from an upgrade to Outperform at Leerink Swann, citing a better outlook for EpiPen sales and optimism over the company's 2013 guidance. The firm ups its price target to $30 from $26.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
